

Almirall and Happify Health enter into strategic partnership to develop evidence-supported digital therapeutics solutions for psoriasis patients

- **The goal of this strategic partnership is to develop digital solutions to improve the lives of patients with psoriasis based on cognitive behavioral therapy, positive psychology and mindfulness**
- **The CLARO powered by Happify platform will be rolled out across Europe in 2021**

Almirall, S.A. (BME:ALM), a global biopharmaceutical company based in Barcelona, and Happify Health, a leader in digital therapeutics solutions to improve mental and physical health based in New York, will develop a version of its digital platform specifically for people with psoriasis in Spain, UK, Italy and France to be rolled out this year. It is estimated that 20-30% of patients with moderate to severe psoriasis suffer from mental health issues such as anxiety and depression¹. Happify Health, through evidence-based and clinically validated platforms, delivers mental health solutions targeted to patients with chronic diseases.

The Almirall partnership with Happify Health will focus on a solution called CLARO targeted to addressing the mental health concerns of psoriasis patients. The goal of the CLARO program is to create a solution/service to help psoriasis patients improve their well-being when living with a chronic disease providing a meaningful, dynamic and fun user experience. CLARO will be delivered through the Almirall patient support program.

This new partnership demonstrates Almirall's commitment to deliver digital solutions to patients suffering from psoriasis. *"We are so pleased to be joining Happify Health on their mission to improve the lives of patients with chronic conditions. This partnership will allow us to provide patients with psoriasis a solution based on a clinically validated positive psychology platform. We selected Happify as our partner as they have already demonstrated a positive impact on the mental health of patients with chronic conditions, including psoriasis, in published research,"* said Francesca Domenech Wuttke, Chief Digital Officer at Almirall.

"Since mental health events act as stressors that can trigger psoriasis flare ups, Happify is excited to work with a European leader like Almirall in this condition to address the mental and physical health symptoms of these patients," said Chris Wasden, Head of Digital Therapeutics at Happify Health. *"Our digital therapeutic solution acts as a complement to Almirall's commitment to psoriasis patients to empower people with psoriasis to live full lives through meaningful behavior change. Together, we can help psoriasis patients, one patient at a time, and at scale."*

About Almirall

Almirall is a global biopharmaceutical company focused on skin health. We collaborate with scientists and healthcare professionals to address patient's needs through science to improve their lives. Our Noble Purpose is at the core of our work: "Transform the patients' world by helping them realize their hopes and dreams for a healthy life". We invest in differentiated and groundbreaking medical dermatology products to bring our innovative solutions to patients in need.

The company, founded in 1943 and headquartered in Barcelona, is publically traded on the Spanish Stock Exchange and is a member of the IBEX 35 (ticker: ALM). Throughout its 77-year history, Almirall has retained a strong focus

on the needs of patients. Currently, Almirall has a direct presence in 21 countries and strategic agreements in over 70, through 13 subsidiaries, with about 1,800 employees. Total revenues in 2019 were 908.4 million euros.

For more information, please visit almirall.com

About Happify Health

Happify Health is a global healthcare platform that combines digital therapeutics and care delivery solutions to improve mental and physical health. Incorporating advanced AI, Happify Health's effective, evidence-based connected platform uses scientific research from positive psychology, cognitive behavioral therapy and mindfulness, combined with a gamified approach and leading-edge technology, to positively impact everyday lives. Happify Health's unique end-to-end, personalized approach emphasizes the mind-body connection and implements meaningful behavior change to address the stress, anxiety and depression that is often comorbid for people living with chronic conditions. The platform offers a multi-channel suite of products for employers, health plans, pharmaceutical companies and consumers. Available in 10 languages, Happify Health's science-led, clinically-validated platform provides access to a comprehensive intervention catalog, delivering better health outcomes by design. For more information, visit www.happifyhealth.com

Almirall Media contact:

Tinkle

Pilar Colomer

pcolomer@tinkle.es

Phone: (+34) 93 93 545 0861

Happify Health Media Contact:

Britta Franson

Director, PR & Communications

britta@happify.com

Almirall Corporate Communications contact:

Francesca Wuttke

francesca.wuttke@almirall.com

Phone.: (+34) 932 913 000

Almirall Investors' relations contact:

Pablo Divasson del Fraile

pablo.divasson@almirall.com

Phone.: (+34) 932 913 087

Legal warning

This document includes only summary information and is not intended to be exhaustive. The facts, figures and opinions contained in this document, in addition to historical information, are "forward-looking statements". These statements are based on the information currently available and the best estimates and assumptions that the Company considers reasonable. These statements involve risks and uncertainties beyond the control of the Company. Therefore, actual results may differ materially from those declared by such forward-looking statements. The Company expressly waives any obligation to revise or update any forward-looking statements, goals or estimates contained in this document to reflect any changes in the assumptions, events or circumstances on which such forward-looking statements are based, unless required by the applicable law.

If you wish to unsubscribe from any Almirall Corporate communication [click here](#).

In accordance with the General Data Protection Regulation and the applicable local regulations, we inform you that your personal data is processed by Almirall S.A. with registered address at Ronda del General Mitre, 151, 08022, Barcelona (Spain), acting as Controller in line with the purposes indicated in our Privacy Policy. For further information, you may consult <https://www.almirall.com/privacy-policy> or contact our Data Protection Officer at the e-mail address: dpo.global@almirall.com. PRNewswire is the Agency that licenses your personal data according to their privacy policy: <https://gdpr.cision.com/gdpr>. At any time you can exercise your rights of access, rectification, deletion, objection, portability as well as the limitation of the processing of your data in the terms provided in the current regulations on Data Protection, by addressing the corresponding written request to our postal address (Ronda General Mitre, 151, 08022 Barcelona, Spain). The request to exercise any of your rights must be accompanied by a copy of an official document that identifies you (ID, driver's license or passport). Finally, we inform you that you can contact the Spanish Data Protection Agency and any other competent public bodies for any claim arising from the processing of your personal data.

References

¹ H.L. Richards, D.G. Fortune, C.E. Griffiths, C.J. Main The contribution of perceptions of stigmatisation to disability in patients with psoriasis J Psychosom Res., 50 (2001), pp. 11-15.

The prevalence of comorbid depression in patients with psoriasis is estimated at between 20% and 30%, and rates as high as 62% have been reported. E.A. Dowlatshahi, M. Wakke, L.R. Arends, T. Nijsten The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: A systematic review and meta-analysis J Invest Dermatol., 134 (2014), pp. 1542-1551.

M. Esposito, R. Saraceno, A. Giunta, M. Maccarone, S. Chimenti An Italian study on psoriasis and depression Dermatology., 212 (2006), pp. 123-127.